Gemfibrozil reduces major cardiovascular events in diabetic men who have both coronary heart disease and a low high-density lipoprotein cholesterol level.
It is also effective in non-diabetics who have a high fasting plasma insulin level, according to investigators from multiple American institutions involved in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT).
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!